Evidence map›Paper›PMID 32869028›Full record

ArticlebioRxiv : the preprint server for biology2021

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL

Maren de Vries, Adil S Mohamed, Rachel A Prescott, Ana M Valero-Jimenez, Ludovic Desvignes, Rebecca O'Connor, Claire Steppan, Joseph C Devlin, Ellie Ivanova, Alberto Herrera and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 24 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Maren de VriesDepartment of Microbiology, New York University Grossman School of Medicine, New York 10016, USA.
Adil S MohamedDepartment of Microbiology, New York University Grossman School of Medicine, New York 10016, USA.
Rachel A PrescottDepartment of Microbiology, New York University Grossman School of Medicine, New York 10016, USA.
Ana M Valero-JimenezDepartment of Microbiology, New York University Grossman School of Medicine, New York 10016, USA.
Ludovic DesvignesDepartment of Medicine, New York University Grossman School of Medicine, New York 10016, USA.
Rebecca O'ConnorPfizer Discovery Sciences, Groton, CT 06340, USA.
Claire SteppanPfizer Discovery Sciences, Groton, CT 06340, USA.
Joseph C DevlinVilcek Institute of Graduate Biomedical Sciences, New York University Grossman School of Medicine, New York 10016, USA.
Ellie IvanovaDepartment of Pathology, New York University Grossman School of Medicine, New York 10016, USA.
Alberto HerreraDepartment of Pathology, New York University Grossman School of Medicine, New York 10016, USA.
Austin SchinleverDepartment of Microbiology, New York University Grossman School of Medicine, New York 10016, USA.
Paige LooseDepartment of Microbiology, New York University Grossman School of Medicine, New York 10016, USA.
Kelly RugglesInstitute of Systems Genetics, New York University Grossman School of Medicine, New York 10016, USA.
Sergei B KoralovDepartment of Pathology, New York University Grossman School of Medicine, New York 10016, USA.
Annaliesa S AndersonPfizer Vaccine Research and Development, Pearl River, NY 10695, USA.
Joseph BinderPfizer Oncology Research and Development, San Diego, CA 92128, USA.
Meike DittmannDepartment of Microbiology, New York University Grossman School of Medicine, New York 10016, USA.
New York University · USPfizer (United States) · USOffice of Science · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Microbial triggers and molecular mechanisms of Th17 mediated airway inflammation-Resubmission-1R01HL125816 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KORALOV, SERGEI BORISOVICH · 2015 to 2019
$3.3M
ELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activityR01AI143639 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 2019 to 2023
$2.5M
SERPINs as a novel family of innate antiviral molecules - Resubmission - 1R21AI139374 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DITTMANN, MEIKE · 2019 to 2020
$466k
NCI NIH HHS P30 CA016087NHLBI NIH HHS R01 HL125816NIAID NIH HHS R01 AI143639NIAID NIH HHS R21 AI139374
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19). There is a dire need for novel effective antivirals to treat COVID-19, as the only approved direct-acting antiviral to date is remdesivir, targeting the viral polymerase complex. A potential alternate target in the viral life cycle is the main SARS-CoV-2 protease 3CL

Identifiers

PMID32869028
PMCPMC7457613
OpenAlexW3157086503

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.